You are here
RECOMBINANT WEST NILE VIRUS VACCINE ADJUVANTED WITH SLA-LSQ
Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 75N93022C00034
Agency Tracking Number: 75N93022C00034
Amount:
$2,997,218.00
Phase:
Phase II
Program:
SBIR
Solicitation Topic Code:
105
Solicitation Number:
PHS-2022-1
Timeline
Solicitation Year:
2021
Award Year:
2022
Award Start Date (Proposal Award Date):
N/A
Award End Date (Contract End Date):
N/A
Small Business Information
650 Iwilei Road, Suite 204
HONOLULU, HI
96817-5318
United States
DUNS:
113226823
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: DAVID CLEMENTS
Phone: (808) 792-1303
Email: clements@HIBIOTECH.COM
Phone: (808) 792-1303
Email: clements@HIBIOTECH.COM
Business Contact
Name: Kent Harada
Phone: (808) 792-1336
Email: kharada@hibiotech.com
Phone: (808) 792-1336
Email: kharada@hibiotech.com
Research Institution
N/A
Abstract
The contract supports the development of TLR4 agonist within an oil-in-water emulsion as a vaccine adjuvant. The adjuvant development activities are being conducted within the context of vaccines to protect against West Nile virus infection.
* Information listed above is at the time of submission. *
